November 24, 2020
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: | David Gessert |
Re: | Emerald Health Pharmaceuticals Inc. |
Offering Statement on Form 1-A
File No. 024-10810
Dear Mr. Gessert:
Emerald Health Pharmaceuticals Inc., a Delaware corporation, hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Offering Statement to become qualified at 5:00 PM Eastern Time on November 24, 2020 or as soon thereafter as possible.
Should you have any questions or require any additional information with respect to this filing, please contact Rebecca Distefano at (954) 768-8221. Thank you for your assistance and cooperation.
Very truly yours,
EMERALD HEALTH PHARMACEUTICALS INC.
/s/ Dr. James M. DeMesa
Dr. James M. DeMesa
Chief Executive Officer
Emerald Health Pharmaceuticals Inc. | 5910 Pacific Center Blvd. Ste 320, San Diego, CA 92121 | www.emeraldpharma.life